← All trials
NCT06497517
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 9, 2024
- Primary completion
- Aug 22, 2024
- Completion date
- Aug 22, 2024
- First posted
- Jul 11, 2024
- Last posted
- Aug 27, 2024
- Enrollment
- 14
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.